US20160030484A1 - Mammalian pluripotent stem cells, methods for their production, and uses thereof - Google Patents

Mammalian pluripotent stem cells, methods for their production, and uses thereof Download PDF

Info

Publication number
US20160030484A1
US20160030484A1 US14/816,661 US201514816661A US2016030484A1 US 20160030484 A1 US20160030484 A1 US 20160030484A1 US 201514816661 A US201514816661 A US 201514816661A US 2016030484 A1 US2016030484 A1 US 2016030484A1
Authority
US
United States
Prior art keywords
cells
nerve
population
nedaps
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/816,661
Other languages
English (en)
Inventor
Michael H. Heggeness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas filed Critical University of Kansas
Priority to US14/816,661 priority Critical patent/US20160030484A1/en
Assigned to UNIVERSITY OF KANSAS reassignment UNIVERSITY OF KANSAS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEGGENESS, MICHAEL H.
Publication of US20160030484A1 publication Critical patent/US20160030484A1/en
Priority to US16/375,006 priority patent/US10787658B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system

Definitions

  • Stem cells are partially or fully undifferentiated cells found in most, if not all, multi-cellular organisms. Stem cells have the ability to self-renew through mitotic cell division and to differentiate into a diverse range of specialized cell types, including but not limited to brain, bone, cartilage, glands, muscle, liver, skin, blood vessels, neural, and blood cells. Because stem cells have the potential of developing into specific types of cells and can proliferate more-or-less indefinitely or undergo renewal for extended periods of time, they hold particular potential in the context of therapeutic applications. Stem cells, whether they are pluripotent or multipotent, may be used for organ repair and replacement, cell therapies for a variety of diseases including degenerative diseases, gene therapy, and testing of new drugs for toxicities or desired activities.
  • ESCs embryonic stem cells
  • IPSCs induced Pluripotent Stem Cells
  • iPS cells are created by introducing genetic material into the nucleus of a differentiated “adult” cell to force expression of 4 transcription factors that govern the embryonic phenotype, namely c-Myc, Klf4, Sox2, and Oct4. Takakashi K. and Yamanaka S., Cell (2006) 126(4):663-76; Takahashi et al., Cell (2007) 131(5): 861-872.
  • the genes are often introduced using retrovirus or lentivirus vectors.
  • the vectors that are used to induce the cell to change into an iPS cell become integrated into the host cell genome. These events cause the cell to behave like an embryonic stem cell.
  • iPS cells also have the potential problems identified above, most notably immune rejection, but in addition have the real risk of differentiating into malignant tumors of various types because of the genetic manipulation.
  • Transgenes are largely silenced in iPS cells, but the late reactivation of such transgenes is possible.
  • a significant concern is that the transgene encoding c-Myc could lead to tumorigenesis. Yamanaka S, Cell (2009)137(1):13-17.
  • the present disclosure provides Nerve derived adult pluripotent stem cells (referred to herein as NEDAPS cells), methods for obtaining them, cells differentiated therefrom, and uses of the NEDAPS cells and their differentiated progeny.
  • the NEDAPS cells express Oct4, Sox2, c-Myc, and Klf4, which are four transcription factors that are markers of embryonic and pluripotent stem cells.
  • the NEDAPS cells described here can be derived from peripheral nerves and, without being bound by any particular theory of operation, appear to represent the result of specific stimulation of a reservoir of quiescent cells that transform into NEDAPS cells.
  • NEDAPS cells can differentiate into a wide variety of cell types as described herein, are not derived from an embryonic source, and do not require the manipulation of, or introduction of, new genetic material to the NEDAPS cell nucleus. Such cells can be safely harvested from a subject exposed to NEDAPS cell proliferation conditions or from a nerve exposed to NEDAPS cell proliferation conditions ex vivo.
  • the NEDAPS cells can be cultured in vitro or ex vivo, and propagated with or without differentiation for use in medical, veterinary, or industrial applications. For instance, NEDAPS cells can be harvested from a subject, cultured and propagated in vitro, and then reimplanted in the subject if the subject is in need of stem cell therapy, without expected risk of immune rejection of these self-derived cells.
  • NEDAPS cells can be used for tissue repair or they can be completely or partially differentiated in culture. When implanted following complete differentiation, the progeny of the NEDAPS cells can develop into a selected tissue or organ (e.g., liver tissue) in situ. Autologous implantation of NEDAPS cells or their differentiated progeny circumvents issues associated with harvesting ESCs from embryos and circumvents immune rejection responses associated with implantation of donor tissue. Use of NEDAPS cells and their progeny is also expected to eliminate or drastically reduce the risk of teratoma formation and malignancy in transplant or stem cell therapies.
  • tissue or organ e.g., liver tissue
  • FIGS. 1A-1N show a normal mouse sciatic nerve (control) surgically excised and stained with hematoxylin and eosin.
  • FIG. 1B shows a mouse sciatic nerve, surgically excised 24 hours after exposure to BMP2 by percutaneous injection, stained with hematoxylin and eosin. Note the proliferation of cells.
  • FIG. 1C shows a mouse sciatic nerve 48 hours after exposure to BMP2 by injection, stained with H&E stain. Note the exuberant proliferation of cells.
  • FIG. 1D shows a mouse sciatic nerve 24 hours after exposure to BMP2, stained for Oct4.
  • FIG. 1E shows a mouse sciatic nerve 24 hours after exposure to BMP2, stained for nanog.
  • FIG. 1A shows a normal mouse sciatic nerve (control) surgically excised and stained with hematoxylin and eosin.
  • FIG. 1B shows a mouse sciatic nerve, surgically excised 24 hours after exposure to BMP2 by percutaneous injection, stained with he
  • FIG. 1F shows a mouse sciatic nerve 24 hours after exposure to BMP2, stained for Sox2. Note the proliferation of cells, the majority of which are expressing Sox2.
  • FIG. 1G shows a mouse sciatic nerve 24 hours after exposure to BMP2, stained for Klf4. Note the proliferation of cells, the majority of which are expressing Klf4.
  • FIG. 1H shows a mouse sciatic nerve 24 hours after exposure to BMP2, stained for Interleukin 1, an inflammatory marker.
  • FIG. 1I shows a mouse sciatic nerve 72 hours after exposure to BMP2, stained for Oct4. Note the proliferation of cells, the majority of which are expressing Oct4.
  • FIG. 1J shows a mouse sciatic nerve 48 hours after exposure to BMP2, stained with Sox2. Note the proliferation of cells, the majority of which are expressing Sox2.
  • FIG. 1G shows a mouse sciatic nerve 24 hours after exposure to BMP2, stained for Klf4. Note the proliferation of cells, the majority of which are expressing Klf4.
  • FIG. 1H shows a mouse sci
  • FIG. 1K shows a mouse sciatic nerve 72 hours after exposure to BMP2, stained for Sox2. Note the proliferation of cells, the majority of which are expressing Sox2.
  • FIG. 1L shows a mouse sciatic nerve 72 hours after exposure to BMP2, stained for Oct4. Note the proliferation of cells, the majority of which are expressing Oct4.
  • FIG. 1M shows a mouse sciatic nerve 72 hours after exposure to BMP2, stained for c-Myc. Note the proliferation of cells, the majority of which are expressing c-Myc.
  • FIG. 1N shows a mouse sciatic nerve 24 hours after exposure to BMP2, stained for c-Myc. Note the proliferation of cells, the majority of which are expressing c-Myc.
  • FIGS. 2A-2F show a normal mouse sciatic nerve in a tissue specimen from an untreated (control) mouse stained for Oct4. Oct4 is not expressed in the unstimulated nerve.
  • FIG. 2B shows a mouse sciatic 24 hours after direct exposure to BMP2 by intramuscular (IM) injection stained for Oct4. Note the exuberant cell proliferation and the markedly abnormal nerve. The nuclei of the proliferating cells are densely stained for this stem cell marker.
  • FIG. 2C shown a normal mouse sciatic nerve in a tissue specimen from an untreated (control) mouse stained for c-Myc. c-Myc expression is only minimally expressed in the unstimulated nerve.
  • FIG. 1A shows a normal mouse sciatic nerve in a tissue specimen from an untreated (control) mouse stained for Oct4. Oct4 is not expressed in the unstimulated nerve.
  • FIG. 2B shows a mouse sciatic 24 hours after direct exposure to BMP2 by intramuscular (IM) injection stained for Oct4. Note the exuberant cell proliferation and the marked
  • FIG. 2D shows a histologic section of mouse sciatic nerve and surrounding tissue 24 hours after BMP2 injection, stained for c-Myc. Note the exuberant cellular proliferation, and dense nuclear peroxidase staining for c-Myc in the proliferating cells.
  • FIG. 2E shows a normal mouse sciatic nerve from an untreated (control) mouse stained for Klf4. The unstimulated shows no expression of Klf4.
  • FIG. 2F shows an oblique section through the sciatic nerve in a mouse hamstring muscle harvested 48 h after IM BMP2 injection, stained for Klf4. Note the exuberant cellular proliferation and migration through tissue planes, and the positive peroxidase staining for Klf4.
  • FIG. 2G shows the remains of a mouse sciatic nerve 72 h after exposure to BMP2 by IM injection, after immunostaining for Sox2. Note the loss of integrity of the nerve and the dense nuclear peroxidase staining.
  • FIG. 3 shows cultured NEDAPS cells produced using mechanical compression stained for the nonspecific nuclear stain DAPI (left panel), Sox2 (second panel from left), and c-Myc (third panel from left).
  • the right panel is an overlay of the DAPI, Sox2 and c-Myc images.
  • FIG. 4 shows NEDAPS cells produced using mechanical compression stained for the nonspecific nuclear stain DAPI (left panel), Sox2 (second panel from left), and Oct4 (third panel from left).
  • the right panel is an overlay of the DAPI, Sox2 and Oct4 images.
  • FIG. 5 shows NEDAPS cells produced using mechanical compression stained for the nonspecific nuclear stain DAPI (left panel), Klf4 (second panel from left), and c-Myc (third panel from left).
  • the right panel is an overlay of the DAPI, Klf4 and c-Myc images.
  • FIG. 6 shows NEDAPS cells produced using mechanical compression stained for the nonspecific nuclear stain DAPI (left panel), Klf4 (second panel from left), and Oct4 (third panel from left).
  • the right panel is an overlay of the DAPI, Klf4 and Oct4 images.
  • FIG. 7 shows NEDAPS cells produced using mechanical compression stained for the nonspecific nuclear stain DAPI (left panel), Sox2 (second panel from left), and Klf4 (third panel from left).
  • the right panel is an overlay of the DAPI, Sox2 and Klf4 images.
  • FIG. 8 shows NEDAPS cells produced using mechanical compression stained for DAPI (left panel), Oct4 (second panel from left), and c-Myc (third panel from left).
  • the right panel is an overlay of the DAPI, Oct4 and c-Myc images.
  • FIG. 9 shows PCR gels demonstrating the expression of Oct4, Sox2, c-Myc, and Klf4 in NEDAPS cells.
  • M displays molecular weight markers; Oct4, Sox2, c-Myc, and Klf4 PCR products are shown in panels A-D, respectively.
  • Lanes 1-2 in each panel display PCR products from duplicate preparations of nerves stimulated by simple mechanical compression and harvested at 48 hours, and lanes 3-4 in each panel display PCR products from duplicate preparations of nerves exposed to rhBMP2 by direct application in vivo and harvested at 48 hours.
  • FIG. 10 is a plain micrograph showing the typical morphology of NEDAPS cells grown in restrictive stem cell media. Note the flattened cell shape and adherence to substrate. This morphology is distinctly different from embryonic stem cells, which are typically round and minimally adherent to substrate.
  • FIG. 11 shows a PCR gel demonstrating the expression of markers of osteoblast and endothelial differentiation in NEDAPS cells that had been cultured in media to induce osteoblastic and endothelial cells, respectively.
  • M displays molecular weight markers; Lanes 1-4 of panel A show osteopontin, type I collagen, osteocalcin, and a negative control PCR product, respectively. Lanes 1-3 of panel B show Flt-1, Flk-1, and a negative control PCR product, respectively.
  • FIG. 12 shows a confluent culture of NEDAPS cells that had been cultured in osteogenic culture media to induce differentiation into osteoblasts after staining for alkaline phosphatase activity (marker of osteoblastic differentiation). Note the accumulation of dye indicating the presence of this enzymatic activity which is characteristic of osteoblasts.
  • FIG. 13 shows NEDAPS cells cultured in osteogenic media.
  • the upper left panel shows cells after fluorescence immunostaining for the osteoblast marker type I collagen.
  • the upper right panel shows the same field as the upper left panel imaged with Nomarski optics.
  • the bottom left panel shows a composite of the immunostained and the Nomarski images.
  • the bottom right panel is blank.
  • FIG. 14 is a plain micrograph of NEDAPS cells that have been induced to differentiate into an endothelial phenotype.
  • the round appearance of the cell bodies and long narrow processes are typical of cultured endothelial cells before they become confluent, after which the array of rounded cell bodies displays a “cobblestone” appearance.
  • FIG. 15 shows four different micrographs of NEDAPS cells that have been cultured in an endodermal differentiation medium. Note that the morphology of these differentiated cells is quite distinct from the NEDAPS cells from which they were derived, displaying a more rounded shape, with a less intimate adherence to the substrate, and larger nuclei.
  • FIG. 16 shows four different micrographs of NEDEL cells that have been cultured in an ectoderm differentiation medium. Note that these cells are morphologically quite distinct from the NEDAPS cells from which they were derived, displaying elongated cell shapes consistent with developing nerve tissue.
  • FIG. 17 shows NEDAPS cells produced by stimulating an excised nerve ex vivo.
  • the upper panels show, from left to right, cells immunostained for Klf4, Sox2, Oct4, and c-Myc.
  • the lower panels show the overlays of the fluorescent signals shown in the upper panels on the bright-field images of the same cells.
  • FIG. 18 illustrates exemplary pathways that the NEDAPS cells of the disclosure can be differentiated into.
  • the illustration is abbreviated and does not show every possible cell type or intermediate cell type along each differentiation pathway.
  • hematopoietic stem cells can differentiate into myeloid and lymphoid progenitor cells, which give rise to the myeloid lineage (including red blood cells as shown in FIG. 18 as well as neutrophils, mast cells, etc.) and lymphoid lineage (which includes lymphocytes and natural killer cells), respectively.
  • NEDAPS Cells Mammalian Peripheral Nerve-Derived Stem Cells
  • the present disclosure provides Nerve derived adult pluripotent stem cells (NEDAPS cells) and populations thereof.
  • NEDAPS Nerve derived adult pluripotent stem cells
  • the term “adult” refers to a non-embryonic source. Therefore, the NEDAPS cells can be from a juvenile or adult subject, and the subject can be a mammal, for example, a mouse, a rat, a domesticated mammal such as a cat, dog, rabbit, sheep, pig, cow, goat, or horse, or a primate such as a monkey or human.
  • the NEDAPS cells of the disclosure express the four transcription factors Oct4 (also known as Oct3/4 and POU5F1), Sox2, c-Myc, and Klf4.
  • Oct4 also known as Oct3/4 and POU5F1
  • Sox2 also known as Oct3/4 and POU5F1
  • Sox2 also known as Oct3/4 and POU5F1
  • Sox2 also known as Oct3/4 and POU5F1
  • Sox2 also known as Oct3/4 and POU5F1
  • c-Myc c-Myc
  • Klf4 The gene sequences of these four transcription factors are highly conserved between mammalian species (Fritz et al., Journal of Biological Chemistry (2004) vol. 279(47): 48950-48958; Frankenberg et al., Developmental Biology (2010) vol. 337: 162-170; Rodda et al., Journal of Biological Chemistry (2005) vol. 280(26): 24731-24737; Flynn et al.,
  • somatic cells from mouse, human, rat, and rhesus monkey have been successfully reprogrammed into iPS cells capable of differentiating into all three germ layers (ectoderm, endoderm, and mesoderm) by inducing expression of these same, identical four factors.
  • NEDAPS cells of the disclosure can also express the stem cell markers Nanog and SSEA1.
  • the expression of the transcription factors is not recombinant (e.g., not achieved via introduction of one or more expression vectors encoding one or more of the transcription factors).
  • the NEDAPS cells of the disclosure are capable of differentiating into mesoderm cells (e.g., mesenchymal cells, such as osteoblasts or endothelial cells), endoderm cells, and ectoderm cells (e.g., neural stem cells) when cultured under appropriate differentiation conditions.
  • mesoderm cells e.g., mesenchymal cells, such as osteoblasts or endothelial cells
  • ectoderm cells e.g., neural stem cells
  • Examples of cell types into which the NEDAPS cells can be differentiated are shown in FIG. 18 . Differentiation conditions for various cell type are known in the art and differentiation media are available commercially. Exemplary differentiation conditions described in section 7.2.3.
  • NEDAPS cells are motile both in vivo and in vitro (as evidenced by, for example, cell migration in vivo and migration of recently divided cells in vitro), readily adhere to glass or plastic substrate, and/or only infrequently form colonies.
  • the NEDAPS cells of the disclosure or their partially or completely differentiated progeny can be made recombinant or genetically engineered, e.g., to incorporate a heterologous gene from another species, a homologous gene from the same species (for example, to replace a gene that is mutant in the subject from whom the NEDAPS cells are derived), to express an engineered protein whose function is improved or altered relative to a wild type protein, or to incorporate a marker (e.g., a detectable marker or nucleic acid tag) to permit identification of the NEDAPS cells or their progeny, for example to track their fate following implantation.
  • a marker e.g., a detectable marker or nucleic acid tag
  • Nucleic acids can be introduced into a NEDAPS cell using methods known to persons skilled in the art (e.g., by the methods described in Wang and Gao, Discov Med. (2014) vol. 18 (97):67-77, the contents of which are incorporated by reference herein), and can be incorporated into the genomic DNA or not incorporated into the genomic DNA of the NEDAPS cell.
  • nucleic acids can be introduced into a NEDAPS cell by a recombinant virus (e.g., a retrovirus or a lentivirus), injection of naked DNA, or transfection (e.g., by a method using calcium phosphate, liposomes, or electroporation).
  • the disclosure provides NEDAPS cells, populations of NEDAPS cells, and cells and populations of cells differentiated therefrom, e.g., mesoderm cells (such as mesenchymal stem cells, osteoblasts, and endothelial cells), endoderm cells, or ectoderm cells (such as neural stem cells).
  • mesoderm cells such as mesenchymal stem cells, osteoblasts, and endothelial cells
  • endoderm cells such as neural stem cells
  • ectoderm cells such as neural stem cells.
  • a population is characterized by one, two, or all three characteristics:
  • the population is at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or more than 99% homogeneous, e.g., for a population of NEDAPS cells that is at least 80% homogeneous, at least 80% of the cells in the population are NEDAPS cells.
  • the population contains at least 50 cells, at least 100 cells, at least 200 cells, at least 500, at least 1,000 cells or at least 10,000 cells.
  • the disclosure is also directed to any and all permutations of the foregoing embodiments of characteristics (b) and (c) is, e.g., the population is at least 75% homogeneous and contains at least 200 cells, or the population is at least 60% homogeneous and contains at least 100 cells, or the population is at least 90% homogeneous and contains at least 50 cells.
  • NEDAPS cells and populations thereof can be produced by culturing a peripheral nerve exposed to NEDAPS cell proliferation conditions ex vivo or by culturing cells from a peripheral nerve exposed to NEDAPS cell proliferation conditions in a subject in vivo.
  • peripheral nerve includes peripheral nerves that have been disrupted as described herein. Nerves suitable for generating NEDAPS cells include peripheral nerves that are routinely harvested surgically for nerve grafts subjects who have sustained an injury to a functionally important nerve.
  • the peripheral nerve can be, for example, a sural nerve, a branch of a sural nerve, a proper digital nerve of a finger or toe, a gracilis branch of an obturator nerve, a segment of a medial antebrachial cutaneous nerve, a lateral antebrachial cutaneous nerve, a proximal third webspace fascicle nerve, a posterior intraosseous nerve or other peripheral nerve.
  • NEDAPS cell proliferation conditions can comprise exposing the peripheral nerve to a cytokine such as a member of the bone morphogenic protein (BMP) family of cytokines.
  • BMP bone morphogenic protein
  • a preferred BMP protein for use in producing NEDAPS cells is BMP2, such as recombinant human BMP2 (rhBMP2).
  • rhBMP2 is marketed by Medtronic as INFUSE®, and is FDA approved for stimulating bone formation.
  • Studies have suggested that BMP2 induces neuroinflammation, and it is thought that this neuroinflammation may be basic to the process of BMP2-induced bone formation. Heggeness, The Spine Journal , (2011) 11:506. Similar neuroinflammatory responses following BMP2 exposure have been observed in mouse, rat, and human.
  • NEDAPS cells can be produced in vivo in a subject by directly applying a solution of BMP2 (e.g., a saline solution containing BMP2) to a surgically exposed peripheral nerve or by intramuscular (IM) injection to a site in the vicinity of a peripheral nerve.
  • BMP2 e.g., a saline solution containing BMP2
  • IM intramuscular
  • BMP2 can be directly applied to an exposed nerve or injected to a site in the vicinity of a peripheral nerve, typically in an amount ranging from 10 ng to 1 mg.
  • the amount of BMP2 is 10 ng, 25 ng, 40 ng, 50 ng, 60 ng, 75 ng, 100 ng, 150 ng, 200 ng, 250 ng, 300 ng, 400 ng, 500 ng, 750 ng or 1 mg, or selected from a range bounded any pair of the foregoing values, e.g., 10 ng to 250 ng, 40 ng to 75 ng, 50 ng to 300 ng, 60 ng to 150 ng, and so on and so forth.
  • the amount of BMP2 directly applied to an exposed nerve or injected to a site in the vicinity of a peripheral nerve can be provided in a solution having a volume ranging from 1 ⁇ l to 10 ml.
  • the volume is 0.1 ml to 2 ml, e.g., 0.25 ml, 0.5 ml 0.75 ml, 1 ml, 1.25 ml, or selected from a range bounded by any pair of the foregoing values, e.g., 0.1 ml to 1 ml, 0.25 ml to 1 ml, or 0.5 ml to 1.5 ml, and so on and so forth.
  • the amount of BMP2 applied and the volume of BMP2 solution used can be varied depending on the size of the peripheral nerve targeted.
  • NEDAPS cells can be produced in vivo by exposing the subject to conditions that result in local production of BMP2, such as a bone fracture, blunt injury, thermal injury, or electric shock.
  • BMP2 bone fracture
  • NEDAPS cells are obtained from a subject who has suffered a bone fracture, blunt injury, thermal injury, or electric shock.
  • NEDAPS cell proliferation conditions can also comprise exposing the peripheral nerve to a neuroinflammatory agent other than or in addition to BMP2, such as tumor necrosis factor alpha, Interleukin-1 Beta, nerve growth factor, histamine, Interleukin 6, or a combination thereof.
  • a neuroinflammatory agent such as tumor necrosis factor alpha, Interleukin-1 Beta, nerve growth factor, histamine, Interleukin 6, or a combination thereof.
  • NEDAPS cell proliferation conditions comprise applying trauma to a peripheral nerve (in vivo or ex vivo).
  • the trauma can be, for example, mechanical trauma, e.g., compressing the peripheral nerve (e.g., for 1-2 seconds), cutting or severing the peripheral nerve, or mincing the peripheral nerve, electrical stimulation (e.g., overstimulation), an ultrasonic shock wave, or a thermal insult.
  • production of NEDAPS cells can be stimulated by subjecting peripheral nerve tissue to physical injury.
  • NEDAPS cell proliferation can also be achieved by exposing the peripheral nerve to BMP2 ex vivo by culturing the nerve in a medium comprising BMP2 and/or by subjecting the nerve to mechanical trauma (e.g., compression and/or mincing).
  • the concentration of BMP2 in the medium is 5 ng/ml, 10 ng/ml, 25 ng/ml, 40 ng/ml, 50 ng/ml, 60 ng/ml, 75 ng/ml, 100 ng/ml, 150 ng/ml, 200 ng/ml, 250 ng/ml, 300 ng/ml, 400 ng/ml, 500 ng/m, 750 ng/ml or 1 mg/ml, or selected from a range bounded any pair of the foregoing values, e.g., 5 ng/ml to 50 ng/ml, 10 ng/ml to 250 ng/ml, 40 ng/ml to 75 ng/ml,
  • NEDAPS cell proliferation conditions described herein can also be used to produce NEDAPS cells.
  • NEDAPS cells can be produced by exposing a peripheral nerve to a combination of two or three of BMP2, compression, and mincing.
  • the NEDAPS cell proliferation conditions comprise mincing the peripheral nerve with or without exposure to BMP2.
  • the methods of the disclosure for producing NEDAPS cells can be practiced using human subjects and domesticated animals with minimal morbidity by the identification and use of suitable peripheral nerves.
  • suitable nerves for human and veterinary applications are the sural nerve or one of its branches, a proper digital nerve to a central digit in the hand or foot, and a nerve from a limb amputated due to, for example, injury or disease.
  • NEDAPS cells can be harvested and used to generate NEDAPS cells, which can in turn be used for regenerative procedures and processes for that subject (i.e., in an autologous implantation procedure), or for a closely matched subject (i.e., in a closely matched but allogeneic implantation procedure).
  • This technique would be particularly desirable for generating individual genetic “perfect match” cells for tissue engineering and other regenerative therapies in both human and veterinary applications.
  • the peripheral nerve of a subject exposed to NEDAPS cell proliferation conditions in vivo can be harvested, e.g., by surgical excision, from the subject immediately after exposure to NEDAPS cell proliferation conditions or can be harvested after a period of time. In some embodiments, the peripheral nerve is harvested up to 4 days, more preferably up to 3 days after exposure to NEDAPS cell proliferation conditions.
  • the peripheral nerve can be harvested about e.g., about 8 hours (or a third of a day), about 12 hours (or half a day), about 24 hours (or one day), about 48 hours (or two days), or about 72 hours (or three days) after exposure to NEDAPS cell proliferation conditions, or after a period selected from a range bounded by any pair of the foregoing values, e.g., 8 hours to 72 hours (or one third of a day to three days), 8 to 12 hours (or one third of a day to half a day), 12 to 24 hours (or half a day to a day), 24 to 48 hours (or one to two days), or 48 to 72 hours (or two to three days) after exposure to NEDAPS cell proliferation conditions, and so on and so forth.
  • the nerve can optionally be disrupted to facilitate egress of the NEDAPS cells from the nerve.
  • Peripheral nerves exposed to NEDAPS cell proliferation conditions ex vivo can be cultured for a period of time after being exposed to NEDAPS cell proliferation conditions and can be optionally disrupted, either before or after culturing.
  • a peripheral nerve exposed to NEDAPS cell proliferation conditions ex vivo is cultured ex vivo for up to 4 days, more preferably up to 3 days following exposure to NEDAPS cell proliferation conditions, e.g., about 8 hours (or a third of a day), about 12 hours (or half a day), about 24 hours (or one day), about 48 hours (or two days), or about 72 hours (or three days), or for a period selected from a range bounded by any pair of the foregoing values, e.g., from 8 hours to 72 hours (or from one third of a day to three days), from 8 to 12 hours (or from one third of a day to half a day), from 12 to 24 hours (or from half a day to a day), from 24 to 48 hours (or from one
  • Mechanical and/or enzymatic means can be used to disrupt a peripheral nerve.
  • the nerve can be minced, strained and/or subject to treatment with one or more proteases such as trypsin, a collagenase (e.g., a c. histolyticum collagenase), or matrix metalloprotease.
  • proteases such as trypsin, a collagenase (e.g., a c. histolyticum collagenase), or matrix metalloprotease.
  • the cells from a peripheral nerve are cultured in a medium comprising BMP2 after the peripheral nerve has been compressed, harvested, and disrupted by mincing and/or treatment with one or more proteases.
  • cells from a peripheral nerve are cultured in a medium comprising BMP2 after the peripheral nerve has been compressed, harvested, and disrupted by mincing and treatment with one or more proteases.
  • a harvested peripheral nerve, cells from a disrupted peripheral nerve, and isolated NEDAPS cells can be cultured in a non-differentiating medium to maintain the NEDAPS cells in an undifferentiated state.
  • Example 3 describes a suitable medium for culturing NEDAPS cells in a non-differentiated state.
  • Other suitable non-differentiating media are known in the art, many of which are commercially available, e.g., KnockoutTM DMEM (Gibco, catalog no. 10829-018) and mTeSRTM 1 medium (Stemcell Technologies, catalog no. 05857).
  • NEDAPS cells can be cultured from a peripheral nerve without isolating the NEDAPS cells from other cell types present in the nerve.
  • single or multiple NEDAPS cells can be separated from one or more other cell types, e.g., by micromanipulation, flow cytometry, or other methods for sorting or separating cells known in the art, and cultured to generate a population or expanded population of NEDAPS cells.
  • the NEDAPS cell population can be maintained in undifferentiated form standard media or differentiated in a less potent cell type, for example as described in section 7.2.3.
  • the differentiation can be carried out immediately after exposure to proliferation conditions or after maintenance of the NEDAPS cells in undifferentiated form.
  • a population of NEDAPS cells can be differentiated into a less potent cell type by exposing the population to differentiation conditions, for example, by culturing the population in a differentiation medium (or media) that induces stem cells to differentiate into a particular cell type.
  • the NEDAPS cells of the disclosure can be differentiated into cells of the endodermal, mesodermal, and ectodermal lineages. Particular examples of cell types into which the NEDAPS cells can be differentiated are shown in FIG. 18 . Differentiation conditions for various cell types are known in the art and differentiation media are available commercially, such as those for differentiating ESCs or iPS cells. Exemplary methods and media are described in Examples 4-6.
  • the StemXVivoTM Ectoderm Kit (R&D Systems, catalog #SC031), StemXVivoTM Mesoderm Kit (R&D Systems, catalog #SC030), and StemXVivoTM Endoderm Kit (R&D Systems, catalog #SC019) can be used to differentiate the NEDAPS cells into ectoderm, mesoderm, and endoderm cells, respectively, the media described in Example 4 can be used to differentiate a population of NEDAPS cells into osteoblasts or endothelial cells (i.e.
  • the media described in Example 5 can be used to differentiate a population of NEDAPS cells into endoderm cells
  • the media described in Example 6 can be used to differentiate a population of NEDAPS cells into neural stem cells (i.e., an ectoderm cell type).
  • the methods described herein can be used to generate populations of NEDAPS cells and cell types differentiated therefrom, e.g., a population that is characterized by (a) being isolated and/or (b) being at least 50% homogenous and/or (c) containing at least 10 cells, and any of the embodiments thereof as described in Section 7.
  • the populations find particular advantage for autologous applications, i.e., for implantation in the (human or other animal) subject from which the NEDAPS cells were derived.
  • NEDAPS cells and their differentiated progeny can be manipulated ex vivo to generate cells for treatment of a subject.
  • the cells can be used for any condition that benefits from cell or organ regeneration.
  • Particular applications include organ culture, wound healing, e.g., to treat diabetic lower extremity wounds, Charcot arthropathies, pressure ulcers, or bone fractures, nerve regeneration, restoring immune function, hematopoiesis, tissue engineering, gene therapy (e.g., as described in Wang and Gao, Discov Med. (2014) vol. 18 (98):151-161, the contents of which are incorporated by reference herein) and any other medical situation where stem cells grown in culture and induced to differentiate are useful.
  • undifferentiated NEDAPS cells or osteoblasts differentiated from NEDAPS cells can be grown in vitro, and then placed into a site where bone formation is desired, such as a fracture site, a segmental bone defect site (e.g., after a tumor excision) or a site where bone ingrowth into an implant (e.g., an artificial joint component) is desired.
  • a site where bone formation is desired such as a fracture site, a segmental bone defect site (e.g., after a tumor excision) or a site where bone ingrowth into an implant (e.g., an artificial joint component) is desired.
  • undifferentiated NEDAPS cells or endothelial cells that have been differentiated from NEDAPS cells can be propagated in culture, and then placed surgically or injected into an anatomic area where blood vessel formation is desired, such as a limb with a compromised blood supply.
  • fibroblasts differentiated from NEDAPS cells can be propagated in culture, then placed into an anatomic area where soft tissue healing is desired, for example, for treating a slow healing wound such as a diabetic foot ulcer.
  • hematopoietic cells differentiated from NEDAPS cells can be injected into the circulation or into the bone marrow of a subject with anemia. The injected hematopoietic cells can then produce blood cells for the subject.
  • the NEDAPS cells of the disclosure can also be used to evaluate toxicity of pharmaceutical compounds and other chemicals by, for example, using the NEDAPS cells in the methods described in U.S. Pat. No. 8,703,483, the contents of which are incorporated by reference herein.
  • the NEDAPS cells and cells differentiated therefrom can be made recombinant, for example for use in gene therapy.
  • a population of NEDAPS cells or cells differentiated therefrom can be formulated in a pharmaceutically acceptable medium or excipient or a biocompatible and/or biodegradable scaffold or matrix.
  • mice were anaesthetized (under an IACUC approved protocol) and the right sciatic nerve was exposed using standard methods. In 7 animals, 50 nanograms of BMP2 was placed directly on the nerve. In 3 control animals, no agent was applied to the nerve.
  • the untreated nerves appeared normal (see FIG. 1A ), with the exception of perhaps some mild inflammatory findings, thought to be due to the surgical exposure.
  • the BMP2 treated nerves were found to be fragmented and disrupted (see FIG. 1 ), but marked proliferation of cells were noted within the nerves.
  • the treated nerves were noted to fragment spontaneously during and after the sectioning process.
  • the nerves treated with BMP2 were abnormal and very fragile.
  • mice Twenty mice were anaesthetized and 50 ng or 100 ng of BMP2 were injected percutaneously (IM) into the right hamstring muscle of each mouse. The mice were sacrificed at 24, 48, or 72 hours. Hamstring muscles were harvested without dissecting down to the sciatic nerve, but taking care that the harvested tissue contained the usual anatomic location of this nerve. The contralateral (untreated) hamstring muscles were harvested from 4 animals to serve as control tissue.
  • the BMP2 was administered by IM injection, it was difficult to know after tissue harvest and processing how close the site of injection was to any given microscopic field.
  • the sections were stained for an array of stem cell markers and a panel of inflammatory markers.
  • the nerves from limbs injected with BMP2 appeared disrupted and slightly fragmented even in the 24 hour animals (see FIGS. 2B and 2D ).
  • the nerves from the treated animals displayed marked abnormalities by 72 hours (see FIG. 2F ).
  • the 72 hour specimens showed severely abnormal nerves.
  • the abnormal nerves were expressing a preponderance of cells expressing all four ESC markers Oct4, Sox2, c-Myc, and Klf4.
  • mice All animal activities were carried out in the Wichita State University Animal Care Facility and were approved by the Wichita State University Institutional Animal Care and Use Committee. 8 to 12 week-old female BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, Me.) and acclimated to the facility for at least 1 to 6 weeks prior to use in the study. On the day of surgery, the mice received 0.05 mg/kg of buprenorphine by subcutaneous injection one hour before surgery for preventative analgesia. The mice were anesthetized by intraperitoneal injection of 90 mg/kg ketamine and 8 mg/kg Xylazine, supplemented with 1-2% Isoflurane by nose cone.
  • the right leg of each animal was shaved and the surgical area disinfected with Povidone-Iodine and ethanol.
  • An incision was created on the lateral aspect of the thigh, and the sciatic nerve exposed by blunt dissection.
  • the nerve was either manually compressed to approximately 25% of its original diameter using a forceps with a width of 1 mm at four or five sites along the length of the exposed nerve, or exposed to 60 ng of BMP2 in 10 ⁇ l of sterile saline (INFUSE® Bone Graft, Medtronic Spinal and Biologics, Memphis, Tenn.).
  • the incision of each animal was sutured closed and the animal cared for, for 8, 24, 48, or 72 hours until sacrifice by CO 2 inhalation.
  • the nerve was immediately harvested after sacrifice for histologic analysis, cell culture or screening for gene expression using polymerase chain reaction (PCR) methods.
  • PCR polymerase chain reaction
  • mice were also performed using percutaneous injection of BMP2, into the hamstring muscle mass of the mouse posterior thigh. Identical anesthesia, analgesia and euthanasia were employed as above. Animals were sacrificed at 24, 48, and 72 hours post injection. Immediately post mortem, the hamstring muscle mass was harvested by sharp dissection and specimens were fixed in formalin, embedded in paraffin and sectioned. A total of 37 mice were treated by IM injection of 5 ⁇ l of sterile saline containing 60 ng of BMP2 (INFUSE®).
  • NEDAPS cells were isolated from mouse sciatic nerves and cultured according to a published protocols (Wu et al., Biotechnology letters 2009; 31:1703-1708) with modifications. Briefly, sciatic nerve segments were minced to 1 mm pieces in PBS and pelleted by centrifugation at 600 ⁇ g for 5 minutes. The nerve tissue was then incubated at 37° C. in 0.5 ml of 0.2% (0.27 U/ml) collagenase (Worthington Biochemical Corp) in sterile DMEM for 90 minutes, followed by addition of an equal volume of 0.05% trypsin-EDTA solution for 5 minutes with agitation. 300 ⁇ l of heat-deactivated fetal bovine serum (FBS) was added to the mixture to stop the enzyme digestion.
  • FBS heat-deactivated fetal bovine serum
  • the isolated cells were centrifuged down at 600 ⁇ g for 10 min.
  • the cell pellets were resuspended and distributed to 6-well culture dishes, or 4-well chamber-slide in DMEM (Gibco, Life Technologies), supplemented with 20% Knockout serum replacement (KSR, Gibco), 100 ⁇ M MEM non-essential amino-acid solution (Gibco), 1 ⁇ GlutaMAXTM-I (Cat. no.
  • NEDAPS cells double stainings against a pair of ESC markers (Klf4, Sox2, Oct4, and c-Myc) were performed. Briefly, cells grown in chamber slides were fixed with 4% paraformaldehyde for 30 minutes at room temperature, washed 3 ⁇ with PBS, and blocked with 3% normal donkey serum and 0.1% Triton X-100. Primary antibodies include goat anti-Klf4 (R&D), goat anti-Sox2 (Santa Cruz Biotechnology), goat and rabbit anti-Oct4 (Abcom), and rabbit anti-c-Myc (Santa Cruz Biotechnology).
  • Primary antibodies include goat anti-Klf4 (R&D), goat anti-Sox2 (Santa Cruz Biotechnology), goat and rabbit anti-Oct4 (Abcom), and rabbit anti-c-Myc (Santa Cruz Biotechnology).
  • Stained cells were viewed under a TCS SP5 II confocal laser scanning microscope (Leica Microsystems) and images acquired with the LAS Image Analysis optional software.
  • Optical single sections were acquired with a scanning mode format of 1024 ⁇ 1024 pixels, with a pixel size of 0.21 ⁇ m. Acquisition of automated-sequential collection of multi-channel images was performed in order to reduce spectral crosstalk between channels, and individual images of double staining signals were overlaid to generate co-localized images.
  • cDNA Complementary DNA
  • PCR buffer containing 5.5 mM MgCl 2 , 500 ⁇ M each of deoxynucleotide triphosphates, 0.5 U/ ⁇ l RNase inhibitor, 2.5 ⁇ M random hexamers, and 1.25 U/ ⁇ l reverse transcriptase (Perkin-Elmer Cetus, Norwalk, Conn.) on a Veriti 96-well Thermal Cycler (Applied Biosystems, Foster City, Calif.) at 25° C. for 10 minutes, 48° C. for 25 minutes, and 95° C. for 5 minutes.
  • RT-PCR reaction mixtures contained SYBR Green PCR Master Mix (Applied Biosystems), 2 ⁇ l cDNA, and 400 nM tested gene primer pairs were run in a StepOnePlus® Real-Time PCR System (Applied Biosystems) for 40 cycles. The fluorescent signals were dynamically recorded.
  • the primer pairs for each target gene were designed using Primer3 program (bioinfo.ut.ee/primer3-0.4.0/primer3) and constructed by Sigma-Genosys (Woodlands, Tex.). The primer sequences are shown in Table 1.
  • the cells were observed to generally be quite flat and spread across the glass or plastic substrate (see FIG. 10 ), showing that the cells were adherent.
  • the cells could not be “rinsed off” when the media was changed, also showing that the cells adhered to the substrate. Passaging the cells to a new plate required exposing them to trypsin to get them to detach.
  • NEDAPS cells After maintaining NEDAPS cells cultured in embryonic stem cell medium for 5 days, the cells were experimented for differentiation.
  • NEDAPS cells were cultured with osteogenic medium containing 10 mM beta-sodium glycerophosphate, 50 ⁇ ⁇ g/ml ascorbic acid and 10 nM dexamethasone in DMEM/F12 medium, plus 10% fetal bovine serum, 100 mg/ml streptomycin and 100 U/ml penicillin. Alkaline phosphatase staining and type I collagen staining were performed 7 days later to identify the structural and functional properties of the osteoblastic cells.
  • NEDAPS cells directed for endothelial cell differentiation were plated onto flasks coated with fibronectin (Sigma-Aldrich, US) and cultured in endothelial cell basal medium-2 (Lonza Walkersville, Inc. Walkersville, Md.) supplemented with EGMTM-2-MV SingleQuotsTM, containing 5% FBS, 10 ng/ml human epidermal growth factor (hEGF), 50 ng/ml human vascular endothelial growth factor (VEGF), 50 ng/ml human insulin-like growth factor-1 (IGF-1), 1 ⁇ g/ml hydrocortisone, and 100 U/ml penicillin (Invitrogen, US), and 100 ⁇ ⁇ g/ml streptomycin (Invitrogen, US).
  • hEGF human epidermal growth factor
  • VEGF human vascular endothelial growth factor
  • IGF-1 insulin-like growth factor-1
  • hydrocortisone 100 U/ml penicillin (Invitrog
  • alkaline phosphatase (ALP) staining Kit (Sigma-Aldrich, St. Louis, Mo.) was used for the semi-quantitative demonstration of alkaline phosphatase activity in the differentiated osteoblastic cells as described previously (Jiang et al., J Biomed Mater Res A (2013)101:2817-2825). Briefly, alkaline-dye mixture was prepared to dissolve the Fast Violet B capsule and Naphthol AS_MX Alkaline Phosphate in distilled water. After fixation in citrate buffered acetone for 30 seconds, cells were incubated in alkaline-dye mixture for 30 minutes at 26° C. followed by Mayer's Hematoxylin counterstain for 1 min. The resulting insoluble diffuse, red dye deposit within cytoplasm indicates alkaline phosphatase activity. Immunostaining for type I collagen was also performed.
  • Ostin-derived osteogenic markers Ostin-derived osteogenic markers
  • type I collagen type I collagen
  • osteocalcin positive stained for alkaline phosphatase and for type I collagen
  • FIG. 12-13 positive stained for alkaline phosphatase and for type I collagen
  • FIG. 14 expressed endothelial markers Flt-1 and Flk-1 (see FIG. 11 ).
  • NEDAPS cells were induced into the DE lineage using a commercial kit from Gibco (Life Technologies). Briefly, NEDAPS cells were cultured in a 12-well plate with Gibco® Essential 8TM medium at 37° C., 5% CO 2 . On day 1, Essential 8TM medium was replaced with pre-warmed DE Induction Medium A for 24 hours. On day 2, DE Induction Medium A was completely aspirated and replaced with pre-warmed DE Induction Medium B. The plate was incubated at 37° C. for 24 hours. Morphology changes of the cells were monitored under an inverted microscope.
  • the growing cells were morphologically very different from the NEDAPS cells prior to induction.
  • the cells become more rounded (i.e., less squamous) and displayed larger nuclei than undifferentiated NEDAPS cells (see FIG. 15 ), indicating clear differentiation away from NEDAPS cells and development of endodermal characteristics
  • NEDAPS cells were propagated and induced to differentiate into neural stem cells. For proliferation of the cells, NEDAPS cells were cultured in Complete NeuroCultTM NSC Proliferation Medium that contained 10% NeuroCultTM NSC proliferation supplement (v/v) (Stemcell Technologies, catalog no. 05701) in NSC basal medium (Stemcell Technologies, catalog no. 05700). rhEGF at a final concentration of 20 ng/ml was also included in the cultures. When 30% cell confluence was reached, the medium was removed and replaced by Complete NeuroCultTM NSC Differentiation Medium that contained 10% NeuroCultTM NSC differentiation supplement (Stemcell Technologies, catalog no. 05703), and the culture was incubated at 37° C. for two days. Morphology changes of the cells were monitored under an inverted microscope.
  • Complete NeuroCultTM NSC Proliferation Medium that contained 10% NeuroCultTM NSC proliferation supplement (v/v) (Stemcell Technologies, catalog no. 05701) in NSC basal medium (Stem
  • the cells Following culture in the differentiation medium, the cells had a very different morphology than the NEDAPS cells prior to differentiation.
  • These elongated cells displayed features of primitive nerve cells, characteristic of ectoderm.
  • Mouse sciatic nerves were surgically exposed and retrieved using sterile techniques. Gentle compressions were applied for 1-2 seconds along the nerves before dissecting out from the body. Nerve tissue was minced to 1 mm pieces and digested with collagenase and trypsin as described in Example 3. Cells were collected by centrifugation and placed into a 12-well culture plate or 8-well chamber slide in the stem cell medium described in Example 3.
  • BMP2 was added to the medium 24 hours later at a final concentration of 750 ng/ml and cultured for 24 hours, after which this media was evacuated and replaced by the stem cell media described in Example 3: DMEM (Gibco, Life Technologies), supplemented with 20% Knockout serum replacement (KSR, Gibco), 100 ⁇ M MEM non-essential amino-acid solution (Gibco), 1 ⁇ GlutaMAXTM-1 (Cat. no.
  • the cells were stained for Klf4, Sox2, Oct4, and c-Myc.
  • the cells produced using this method express the four embryonic stem cell markers Klf4, Sox2, Oct4, and c-Myc (see FIG. 17 ).
  • a method for inducing production of stem cells in a peripheral nerve comprising:
  • stem cells are selected from the group consisting of totipotent cells, pluripotent cells, multipotent cells, oligopotent cells, unipotent cells, and combinations thereof.
  • exogenous stimulus is one or more of a physical injury, mechanical manipulation, disruption, an electrical stimulus, or exposure to a cytokine.
  • cytokine is a member of the bone morphogenic protein (BMP) family of cytokines.
  • BMP bone morphogenic protein
  • stem cells culturing the stem cells in vitro in a non-differentiating medium to foster the proliferation of stem cells to create a population of stem cells.
  • stem cells culturing the stem cells in vitro in a non-differentiating medium to foster the proliferation of stem cells to create a population of stem cells.
  • tissue progenitor cells is a body of a subject.
  • protease is at least one of a collagenase or a matrix metalloproteinase.
US14/816,661 2014-08-04 2015-08-03 Mammalian pluripotent stem cells, methods for their production, and uses thereof Abandoned US20160030484A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/816,661 US20160030484A1 (en) 2014-08-04 2015-08-03 Mammalian pluripotent stem cells, methods for their production, and uses thereof
US16/375,006 US10787658B2 (en) 2014-08-04 2019-04-04 Mammalian pluripotent stem cells, methods for their production, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462032911P 2014-08-04 2014-08-04
US14/816,661 US20160030484A1 (en) 2014-08-04 2015-08-03 Mammalian pluripotent stem cells, methods for their production, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/375,006 Continuation US10787658B2 (en) 2014-08-04 2019-04-04 Mammalian pluripotent stem cells, methods for their production, and uses thereof

Publications (1)

Publication Number Publication Date
US20160030484A1 true US20160030484A1 (en) 2016-02-04

Family

ID=55178918

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/816,661 Abandoned US20160030484A1 (en) 2014-08-04 2015-08-03 Mammalian pluripotent stem cells, methods for their production, and uses thereof
US16/375,006 Active US10787658B2 (en) 2014-08-04 2019-04-04 Mammalian pluripotent stem cells, methods for their production, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/375,006 Active US10787658B2 (en) 2014-08-04 2019-04-04 Mammalian pluripotent stem cells, methods for their production, and uses thereof

Country Status (7)

Country Link
US (2) US20160030484A1 (ja)
EP (1) EP3194573A4 (ja)
JP (1) JP6698626B2 (ja)
CN (1) CN106687582A (ja)
AU (1) AU2015301342A1 (ja)
CA (1) CA2957071A1 (ja)
WO (1) WO2016022472A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160030484A1 (en) * 2014-08-04 2016-02-04 University Of Kansas Mammalian pluripotent stem cells, methods for their production, and uses thereof
CN106222133A (zh) * 2016-06-29 2016-12-14 湛江经济技术开发区海滨医疗器械有限公司 一种利用冲击波使人体间充质干细胞增殖的方法
CN109280682A (zh) * 2018-08-31 2019-01-29 华子昂 增强血管内皮细胞表达p选择素的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120270313A1 (en) * 2009-06-12 2012-10-25 University Of Kansas Compositions and Methods for Establishing and Maintaining Stem Cells in an Undiffferentiated State
US20130034858A1 (en) * 2010-03-03 2013-02-07 Kyoto University Method for diagnosing a protein misfolding disease using nerve cells derived from ips cells
WO2013188744A1 (en) * 2012-06-15 2013-12-19 Baylor College Of Medicine Perineurium derived adult stem cells and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003572A1 (en) * 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
SG10201607710UA (en) 2008-03-17 2016-11-29 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
EP2128245A1 (en) * 2008-05-27 2009-12-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Generation of induced pluripotent stem (iPS) cells
CN101492676B (zh) * 2008-09-16 2011-02-16 中国科学院广州生物医药与健康研究院 用脑膜细胞生成诱导的多能性干细胞的方法及其用途
WO2010115052A2 (en) * 2009-04-03 2010-10-07 The Mclean Hospital Corporation Induced pluripotent stem cells
WO2011013806A1 (ja) * 2009-07-30 2011-02-03 学校法人慶應義塾 シュワン前駆細胞の製造方法及び増殖方法
US9234179B2 (en) 2009-12-18 2016-01-12 Shanghai Icell Biotechnology Co., Ltd. Materials and methods for generating pluripotent stem cells
CN102884177B (zh) * 2010-02-18 2015-06-10 康干细胞生物技术有限公司 Cd49f通过pi3k/akt/gsk3途径促进成体干细胞的增殖、专能性和重编程
CN102191221B (zh) * 2010-03-17 2014-11-19 中国人民解放军第二军医大学东方肝胆外科医院 一种能无限自我更新的神经干细胞、其制备方法及其用途
US20120069782A1 (en) * 2010-09-22 2012-03-22 Richard Lee-Chee Kuo Method and apparatus for improving drx in a wireless communication system
US20160030484A1 (en) * 2014-08-04 2016-02-04 University Of Kansas Mammalian pluripotent stem cells, methods for their production, and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120270313A1 (en) * 2009-06-12 2012-10-25 University Of Kansas Compositions and Methods for Establishing and Maintaining Stem Cells in an Undiffferentiated State
US20130034858A1 (en) * 2010-03-03 2013-02-07 Kyoto University Method for diagnosing a protein misfolding disease using nerve cells derived from ips cells
WO2013188744A1 (en) * 2012-06-15 2013-12-19 Baylor College Of Medicine Perineurium derived adult stem cells and methods of use
US20150159135A1 (en) * 2012-06-15 2015-06-11 Baylor College Of Medicine Perineurium Derived Adult Stem Cells and Methods of Use

Also Published As

Publication number Publication date
JP6698626B2 (ja) 2020-05-27
CA2957071A1 (en) 2016-02-11
US20190218543A1 (en) 2019-07-18
EP3194573A4 (en) 2018-01-17
WO2016022472A1 (en) 2016-02-11
US10787658B2 (en) 2020-09-29
CN106687582A (zh) 2017-05-17
EP3194573A1 (en) 2017-07-26
JP2017529066A (ja) 2017-10-05
AU2015301342A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
KR101874463B1 (ko) 세포의 재프로그램화 방법 및 이의 용도
KR100973453B1 (ko) 인간 배아 줄기 세포에서 유래되는 연골세포 전구체
US10787658B2 (en) Mammalian pluripotent stem cells, methods for their production, and uses thereof
US20060247195A1 (en) Method of altering cell properties by administering rna
Pannunzio et al. A new method of selecting Schwann cells from adult mouse sciatic nerve
KR101697141B1 (ko) 연골 재생용 세포 치료제
Mantovani et al. Isolation of adult stem cells and their differentiation to Schwann cells
JP2021534813A (ja) 非免疫原性の操作された組織ならびにそれを製造および使用する方法
CN107002035A (zh) 干细胞组合物和生产用于治疗应用的干细胞的方法
Gho et al. Isolation, expansion and neural differentiation of stem cells from human plucked hair: a further step towards autologous nerve recovery
EP2845898B1 (en) Method for culturing neural crest stem cells, and use thereof
Saxena et al. Role of stem cell research in therapeutic purpose--a hope for new horizon in medical biotechnology.
Nauta et al. Adult stem cells in small animal wound healing models
KR20180085699A (ko) 원심분리를 통한 세포 크기별 분리를 이용하여 분화 유도된 연골세포
JP6785516B2 (ja) ヒト臍帯由来間葉系幹細胞から骨芽細胞の製造を目的としたアクチン重合阻害剤による分化誘導技術
KR102306231B1 (ko) 편도 유래 중간엽 줄기세포로부터 건 세포의 분화방법
Edaso et al. Review on applications of stem cells in veterinary therapeutic practices
KR102134428B1 (ko) 면역관용을 가지는 유도만능줄기세포 및 이의 제조방법
Santana et al. History and evolution of regenerative medicine
WO2005095587A1 (ja) 胚性幹細胞から分化した体性幹細胞の製造方法、及びその用途
Sun et al. Pluripotent Stem Cells Can Be Isolated from Human Peripheral Nerves after in vitro BMP-2 Stimulation
WO2019093047A1 (ja) インビトロでの機能的な外分泌腺の製造方法、および、当該方法によって製造される外分泌腺
JP6654323B2 (ja) 重層上皮組織形成能を有する細胞、及びその製造方法
JP2017522909A (ja) 間葉系幹細胞から誘導した万能幹細胞株を製造する方法及び得られた細胞株

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF KANSAS, KANSAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HEGGENESS, MICHAEL H.;REEL/FRAME:036549/0068

Effective date: 20150805

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION